BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29048644)

  • 21. Over-expression of CHAF1A in Epithelial Ovarian Cancer can promote cell proliferation and inhibit cell apoptosis.
    Xia D; Yang X; Liu W; Shen F; Pan J; Lin Y; Du N; Sun Y; Xi X
    Biochem Biophys Res Commun; 2017 Apr; 486(1):191-197. PubMed ID: 28286267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
    Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
    Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of S1PR2 inhibition on epithelial ovarian cancer SKOV3 cell proliferation in vitro and in vivo].
    Dai L; Liu YX; Xie L; Di W
    Zhonghua Fu Chan Ke Za Zhi; 2018 Feb; 53(2):106-110. PubMed ID: 29534379
    [No Abstract]   [Full Text] [Related]  

  • 24. Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target.
    Saed GM; Fletcher NM; Diamond MP; Morris RT; Gomez-Lopez N; Memaj I
    Gynecol Oncol; 2018 Mar; 148(3):567-575. PubMed ID: 29329880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo.
    Zhang X; Liu P; Zhang B; Mao H; Shen L; Ma Y
    Int J Mol Med; 2013 Sep; 32(3):623-8. PubMed ID: 23828376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.
    Kersual N; Garambois V; Chardès T; Pouget JP; Salhi I; Bascoul-Mollevi C; Bibeau F; Busson M; Vié H; Clémenceau B; Behrens CK; Estupina P; Pèlegrin A; Navarro-Teulon I
    MAbs; 2014; 6(5):1314-26. PubMed ID: 25517316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment.
    Qin L; Qiu H; Zhang M; Zhang F; Yang H; Yang L; Jia L; Qin K; Jia L; Dou X; Cheng L; Sang M; Zhang C; Shan B; Zhang Z
    Biomed Pharmacother; 2016 Apr; 79():166-75. PubMed ID: 27044825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The lncRNA HULC functions as an oncogene by targeting ATG7 and ITGB1 in epithelial ovarian carcinoma.
    Chen S; Wu DD; Sang XB; Wang LL; Zong ZH; Sun KX; Liu BL; Zhao Y
    Cell Death Dis; 2017 Oct; 8(10):e3118. PubMed ID: 29022892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
    Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
    Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SYF2 is upregulated in human epithelial ovarian cancer and promotes cell proliferation.
    Yan S; Deng Y; Qiang Y; Xi Q; Liu R; Yang S; Liu J; Tang C; Zhong J; Wang Y
    Tumour Biol; 2015 Jun; 36(6):4633-42. PubMed ID: 25623116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human ovarian cancer stem-like cells can be efficiently killed by γδ T lymphocytes.
    Lai D; Wang F; Chen Y; Wang C; Liu S; Lu B; Ge X; Guo L
    Cancer Immunol Immunother; 2012 Jul; 61(7):979-89. PubMed ID: 22120758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metformin and epithelial ovarian cancer therapeutics.
    Patel S; Kumar L; Singh N
    Cell Oncol (Dordr); 2015 Oct; 38(5):365-75. PubMed ID: 26266765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
    Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
    Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer.
    Sheng X; Li J; Yang L; Chen Z; Zhao Q; Tan L; Zhou Y; Li J
    Oncol Rep; 2014 Jul; 32(1):277-85. PubMed ID: 24859196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transformation of epithelial ovarian cancer stemlike cells into mesenchymal lineage via EMT results in cellular heterogeneity and supports tumor engraftment.
    Jiang H; Lin X; Liu Y; Gong W; Ma X; Yu Y; Xie Y; Sun X; Feng Y; Janzen V; Chen T
    Mol Med; 2012 Oct; 18(1):1197-208. PubMed ID: 22801793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model.
    Yu L; Wang Y; Yao Y; Li W; Lai Q; Li J; Zhou Y; Kang T; Xie Y; Wu Y; Chen X; Yi C; Gou L; Yang J
    Int J Gynecol Cancer; 2014 Sep; 24(7):1158-64. PubMed ID: 24987913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.
    Chen X; Chen S; Xiu YL; Sun KX; Zong ZH; Zhao Y
    Mol Cancer; 2015 Feb; 14(1):31. PubMed ID: 25649143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo.
    Menderes G; Bonazzoli E; Bellone S; Black JD; Lopez S; Pettinella F; Masserdotti A; Zammataro L; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Med Oncol; 2017 May; 34(5):91. PubMed ID: 28397106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary Immunoprevention of Epithelial Ovarian Carcinoma by Vaccination against the Extracellular Domain of Anti-Müllerian Hormone Receptor II.
    Mazumder S; Johnson JM; Swank V; Dvorina N; Martelli E; Ko J; Tuohy VK
    Cancer Prev Res (Phila); 2017 Nov; 10(11):612-624. PubMed ID: 29093011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.